HLAG Antikörper (C-Term) (Biotin)

Produktnummer ABIN94381

Produktdetails anti-HLAG Antikörper (Biotin)

Target: HLAG (HLA Class I Histocompatibility Antigen, alpha Chain G (HLAG))

Bindungsspezifität: C-Term

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser HLAG Antikörper ist konjugiert mit Biotin

Applikation: Western Blotting (WB), ELISA, Flow Cytometry (FACS), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunocytochemistry (ICC)

Spezifität: The mouse monoclonal antibody 5A6G7 was generated to a peptide corresponding to C-intron 4-encoded sequence. This antibody does not crossreact with the full-length HLA-G1 isoform and thus allows to distinguish between secreted HLA-G5 and HLA-G6 isoforms from shedded HLA-G1.

Kreuzreaktivität (Details): Human

Aufreinigung: Purified antibody is conjugated with biotin LC-NHS ester under optimum conditions and unconjugated antibody and free biotin are removed by size-exclusion chromatography.

Immunogen: C-terminal amino acid sequence (22-mer) of soluble HLA-G5 and HLA-G6 proteins coupled to ovalbumin.

Klon: 5A6G7

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: Flow cytometry: Recommended dilution: 1-4 μg/mL. Intracellular staining.

Kommentare:

The purified antibody is conjugated with Biotin-LC-NHS under optimum conditions. The reagent is free of unconjugated biotin.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Do not freeze.
Avoid prolonged exposure to light.

Lagerung: 4 °C

Informationen zur Lagerung: Store at 2-8°C. Do not freeze.

Referenzen für anti-HLAG Antikörper (Biotin) (ABIN94381)

Poláková, Železníková, Russ: "HLA-G5 in the blood of leukemia patients and healthy individuals." in: Leukemia research, Vol. 37, Issue 2, pp. 139-45, (2013) (PubMed).

Lafon, Prehaud, Megret, Lafage, Mouillot, Roa, Moreau, Rouas-Freiss, Carosella: "Modulation of HLA-G expression in human neural cells after neurotropic viral infections." in: Journal of virology, Vol. 79, Issue 24, pp. 15226-37, (2005) (PubMed).

Le Rond, Gonzalez, Gonzalez, Carosella, Rouas-Freiss: "Indoleamine 2,3 dioxygenase and human leucocyte antigen-G inhibit the T-cell alloproliferative response through two independent pathways." in: Immunology, Vol. 116, Issue 3, pp. 297-307, (2005) (PubMed).

Rebmann, Lemaoult, Rouas-Freiss, Carosella, Grosse-Wilde: "Report of the Wet Workshop for Quantification of Soluble HLA-G in Essen, 2004." in: Human immunology, Vol. 66, Issue 8, pp. 853-63, (2005) (PubMed).

Le Rond, Le Maoult, Créput, Menier, Deschamps, Le Friec, Amiot, Durrbach, Dausset, Carosella, Rouas-Freiss: "Alloreactive CD4+ and CD8+ T cells express the immunotolerant HLA-G molecule in mixed lymphocyte reactions: in vivo implications in transplanted patients." in: European journal of immunology, Vol. 34, Issue 3, pp. 649-60, (2004) (PubMed).

Details zu HLAG

Target: HLAG (HLA Class I Histocompatibility Antigen, alpha Chain G (HLAG))

Andere Bezeichnung: HLA-G (HLAG Produkte)

Synonyme: MHC-G antikoerper, B-F antikoerper, B-F-S04 antikoerper, B-F-S05 antikoerper, B-F-S06 antikoerper, B-F-S07 antikoerper, B-FI antikoerper, B-FIV antikoerper, BF2 antikoerper, BFa2 antikoerper, BFw-03 antikoerper, BFw-05 antikoerper, BFz-01 antikoerper, major histocompatibility complex, class I, G antikoerper, MHC BF1 class I antikoerper, HLA-G antikoerper, BF1 antikoerper

Hintergrund: Major histocompatibility complex, class I, G,Human leukocyte antigen G (HLA-G), belonging to MHC class I glycoproteins, plays important roles in both physiological and pathological immunotolerance. It gives an inhibitory signal to cytotoxic T cells, NK cells, monocytes, and some other immune cells. It also induces regulatory T cells and anti-inflammatory macrophages. HLA-G is important e.g. for maternal tolerance to the fetus, and for immunomodulation in particular adult tissues, such as in cornea, pancreatic islets, thymus and other. On the other hand, it is expressed in many solid and hematologic malignancies, where it contributes to evasion of the immune surveillance. HLA-G expression pattern in cancer is an important prognostic factor regarding a poor clinical outcome. Unlike most other MHC glycoproteins, HLA-G acts as an immune checkpoint molecule rather than as an antigen presenting molecule. It concerns both transmembrane and soluble HLA-G isoforms. Among other, HLA-G can promote Th2 immunological response and downregulate Th1 immunological response. For its benefits regarding allograft tolerance, including embryo implantation, soluble HLA-G (sHLA-G) can be used as a marker of developmental potential of embryos during the process of in vitro fertilization. Similarly, sHLA-G concentrations in maternal serum are decreased in preeclampsia. Transplanted patients with increased sHLA-G serum levels have improved allograft acceptance. On the other hand, increased sHLA-G can also indicate presence of malignant (sometimes also of benign) tumor cells. Another important topic is induction of HLA-G expression (sometimes associated with shedding of HLA-G from the cell surface) by some anti-cancer or anti-viral therapies, which can weaken the therapy effect. Monitoring of HLA-G in patients thus has a wide usage.

Gen-ID: 3135

UniProt: P17693

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints